Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
METRONIDAZOLE KABI (Fresenius Kabi Australia Pty Ltd)
Product name
METRONIDAZOLE KABI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
225 working days (255)
Active ingredients
metronidazole
Registration type
New generic medicine
Indication
METRONIDAZOLE KABI (solution for injection) is indicated:
- for treatment of anaerobic infections in patients for whom oral administration is not possible.
- where immediate anti-anaerobic chemotherapy is required.
- where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. Procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.
Note: Metronidazole is inactive against aerobic or facultative anaerobic bacteria.